Safety and Efficacy of RK0202 in Oral Mucositis

Completed · Phase 2

Conditions studied: Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer

In brief

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer. Concurrent chemotherapy is not allowed in the study.

Key facts

Study ID

NCT00230191

Run by

RxKinetix

People needed

110

Starts

2003-01-01

Expected to finish

2005-12-01

Last updated by the study team

2007-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females 18 years and older with confirmed tumors of the oral cavity, oropharynx, nasopharynx, salivary glands, or supraglottic region who are intended for treatment with RT alone (no concomitant chemotherapy).
• In post-operative patients, RT must begin no later than 9 weeks following surgery.
• Intended for treatment with an RT regimen that will deliver a minimum of 60 Gy over 5-8 weeks to at least 2cm2 of three or more of seventeen protocol-specific oral cavity anatomical sites. Each qualifying site must receive a minimum of 60 Gy and there must be at least three such sites. (See section 5.3.1). Regimens may consist of:
• single dose daily fractionated (daily max 2.2 Gy)
• hyperfractionated (daily max 2.4 Gy)
• concurrent boost (daily max during boost 3.3 Gy)
• The minimum planned duration of treatment must be 5 weeks and the maximum 8 weeks.
• Ability to undergo oral assessments.
• Ability to begin dosing with study drug on day 1 of RT.
• Karnofsky Performance Score > 60.
• Ability to understand the protocol and provide informed consent.
• If female, have negative serum pregnancy test.

You may not qualify if…

• Planned use of concomitant chemotherapy.
• Planned use of amifostine.
• Presence of oral mucositis.
• Prior radiotherapy to the head and neck.
• T1 or T2 glottic tumors.
• Other investigational drugs in the 14 days preceding initiation of study medication or during administration of study medication.
• Other investigational or mucoprotective therapy for the prevention of oral mucositis, including, but not limited to, -carotene, tocopherol, laser irradiation, brushing the oral mucosa with silver-nitrate prophylactically, systemic TGF-β (transforming growth factor beta), misoprostol, pentoxifylline, leucovorin, allopurinol mouthwashes, systemic KGF (keratinocyte growth factor) or pilocarpine. Oral rinses with hydrogen peroxide, sucralfate, or chlorhexidine gluconate are also not permitted during the study.
• Serious recent non-malignant medical condition which, in the opinion of the investigator, makes the patient unsuitable for study participation.
• Medical, sociological, or psychological impediment to probable compliance with protocol.
• Inability to undergo repeat treatments, clinical evaluations and other diagnostic procedures required by the protocol.

Where it is running

• UCLA Medical Center — Los Angeles, California, United States
• H Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Commonwealth ENT — Louisville, Kentucky, United States
• University of Connecticutt — Farmington, Massachusetts, United States
• Medical University of Ohio, Cancer Institute Ruppert Cancer Center — Toledo, Ohio, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Cross Cancer Institute — Edmonton, Alberta, Canada
• Juravinski Cancer Center — Hamilton, Ontario, Canada
• University of Ottawa — Ottawa, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.